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Free of acrylamide sodium dodecyl sulphate
(SDS)-based tissue clearing (FASTClear): a
novel protocol of tissue clearing for
three-dimensional visualization of human
brain tissues
In recent years, advances in laser microscopy and
endogenous fluorescent tagging techniques have led to
the development of many tissue-clearing strategies,
which render tissues optically transparent, allowing
large blocks of unsectioned tissue to be visualized in
three dimensions (3D). CLARITY (Clear Lipid-
exchanged Acrylamide-hybridized Rigid Imaging/
Immunostaining/In situ hybridization-compatible Tissue
hYdrogel) is one of the tissue-clearing techniques
which works by fixation/hybridization of brain tissue
using hydrogel cross-links and subsequent detergent-
based delipidation to turn the tissue transparent [1].
Since CLARITY enables molecular probing using
immunofluorescence, this technique was deemed suit-
able for post mortem human brain tissues to demon-
strate the potential in visualizing pathologies in
Alzheimer’s [2], Parkinson’s [3] and neurodevelopmen-
tal disorders [1,4] in 3D. Early attempts using CLARITY
were performed on cortical tissue from the brains of
children [1,4], which is considered to be less myeli-
nated than adults, or on thinly sectioned tissues of up
to 500 lm in thickness [1,2]. In our previous study,
we have demonstrated that CLARITY can successfully
render larger blocks of tissue (about 3 mm in thick-
ness) optically transparent in multiple cortical and sub-
cortical regions of the human brain [3]. However, we
noticed the speed of tissue clearing differs between
regions depending on the degree of myelination, and
duration of formalin fixation. Densely myelinated
regions such as the brainstem and spinal cord in archi-
val formalin-fixed tissues could not be rendered trans-
parent with CLARITY. Also we, and other groups, have
reported tissue expansion after tissue clearing with
CLARITY [5]. Although it was often claimed that the
tissue expansion is a transient effect which will be
adjusted by subsequent refractive index matching [6],
the effects in human brain tissues, especially after
prolonged (>40 days) passive tissue clearing, appeared
to be irreversible [3]. In addition, immunolabelling with
antibodies, particularly on larger samples, remains
challenging because the depth of antibody penetration
is still limited [7]. Many current existing tissue-clearing
protocols are now available and attempts have been
made to improve tissue clearing by combining various
protocols, such as CUBIC with RIMS in CLARITY and
FRUIT (SeeDB with Scale) [8]. Our aim was to develop
an improved and simplified protocol for tissue clearing
in the human brain.
The use of acrylamide hydrogel in the CLARITY pro-
tocol poses a number of problems including those
described above. Tissues embedded with acrylamide
hydrogel undergo expansion upon sodium dodecyl sul-
phate (SDS) clearing and become more fragile as struc-
tural integrity is lost [3,5,9]. In addition, when
transcardial perfusion cannot be performed, diffusion of
hydrogel monomers within a large block of tissue may
be limited, leading to incomplete tissue hydrogel
hybridization [9]. Furthermore, although pores in poly-
acrylamide matrices aid lipid exchange and antibody
penetration can be enhanced by changing composition
of the hydrogel [5], immunolabelling distance appeared
to be better in formaldehyde-fixed, unhybridized tissue
(without acrylamide hydrogel) compared with those
hybridized with both formaldehyde and acrylamide [6].
The original CLARITY study suggested cross-links
between hydrogel and formaldehyde aid fixation of pro-
tein and nucleic acids during the delipidation process.
Protein loss was reported to be significantly lower in
acrylamide-embedded tissues compared with unhy-
bridized tissue after SDS clearing [1,5,6]. However,
there has been no evidence showing the existence of
hydrogel–formaldehyde cross-links. Also, in our
recently published study, no significant protein loss
was found after SDS clearing of formalin-fixed human
brain tissues [10]. Besides, protein loss does not neces-
sarily compromise the quality of immunostaining.
Hence, as long as the tissue is well fixed in formalde-
hyde, we recommend the tissue-clearing procedure to
be simplified by omitting the use of acrylamide-based
hydrogel.
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Prolonged formaldehyde fixation impedes clearing
speed and immunolabelling due to excessive formalde-
hyde cross-links on the tissue. One simple solution is to
use fresh tissue instead of formalin-fixed material. Den-
sely myelinated regions such as brainstem, spinal cord
and cortical white matter are difficult to render transpar-
ent with SDS delipidation [3]. Reiner and colleagues
introduced iDISCO which demonstrated that it is possible
to immunostain a piece of optically opaque, formalde-
hyde-fixed tissue by permeabilizing it in a cocktail of
detergent [11]. The tissue can then be rendered optically
transparent with organic solvents using the 3DISCO
clearing technique [12]. Apart from its delipidation prop-
erties, SDS is known to be a protein denaturant, which
accounts for its use for antigen retrieval in traditional
immunohistochemistry. As a result, to improve immuno-
labelling in tissue clearing, the combination of SDS delip-
idation in CLARITY and detergent permeabilization in
iDISCO can be useful. In addition, we observed that for
densely expressed antigens, such as glial fibrillary acidic
protein GFAP and neurofilament, the use of a low anti-
body concentration (1:1000) with daily supplement (to
a concentration of 1:100–1:50) may be useful to prevent
antibodies being ‘trapped’ at tissue surface.
With the omission of acrylamide–hydrogel in
CLARITY and combination with the iDISCO technique,
we introduce FASTClear (Free of Acrylamide SDS-based
Tissue Clearing) for the immunostaining and three-
dimensional visualization of human brain tissue
(Table 1). First, fresh human brain blocks of up to
1 cm in thickness were fixed in 4% paraformaldehyde
or 10% neutral-buffered formalin at 4°C for 3 days.
Then, the tissue was trimmed to about 3 mm in thick-
ness (the maximum working distance of confocal objec-
tives) before delipidation in 4% SDS-boric acid buffer at
50°C for a minimum of 5 days. Best immunostaining
was achieved if the region of interest is rendered opti-
cally transparent at this stage. However, it is possible
to proceed to immunostaining even if the tissues do not
achieve full transparency at this point. The tissue was
then washed thoroughly in phosphate-buffered saline
(PBS) with 0.1% Triton-X 100 (PBS-Triton) at 50°C
(3 9 1 h). Then, the tissue was permeabilized and
blocked in 0.6 M glycine, 0.2% Triton X-100, 6% Don-
key serum, 20% dimethyl sulfoxide (DMSO) dissolved in
PBS overnight at 37°C. Next, after washing the tissue
in PBS-Triton for 2 9 1 h at 37°C, it was incubated
with primary antibody diluted in 0.2% Tween-20, 5%
DMSO, 3% Donkey serum, 0.01% sodium azide in PBS
for a minimum of 2 days at 37°C. Following another
wash in PBS-Triton (3 9 1 h, then overnight incuba-
tion at 37°C), the tissue was incubated with a sec-
ondary antibody conjugated with Alexa Fluor©
fluorophores diluted in the same diluent as above for
the same number of days as primary antibody incuba-
tion at 37°C. A nuclear counterstain, 40,6-diamidino-2-
phenylindole (1:100 from a stock of 1 lg/ml diluted
with 1:1 water: DMSO), can be added at this stage.
After that, the tissue was washed thoroughly in PBS-
Triton (5 9 1 hr; then overnight) and proceeded to
refractive index matching. For tissues that have been
rendered optically transparent at the delipidation step,
immersion in 47% 2,20-thiodiethanol (vol/vol) in
0.01 M PBS without saline or 70% w/v sorbitol in
0.1 M phosphate buffer as previously described [3] was
done for refractive index matching. For tissues that did
not achieve transparency at the delipidation step (or if
microscope objectives are designed for high refractive
index solution), they can be dehydrated and refractive
index matched as per the 3DISCO protocol [12]. Briefly,
tissue was immersed in 50% tetrahydrofuran (THF)
(overnight), 70% THF (1 h), 80% THF (1 h), 100%
THF (1 h), 100% THF (1 h) and finally dibenzyl ether
until the tissue became optically transparent. Tissues
were then mounted and visualized using a single-
photon or two-photon confocal microscope.
We applied this protocol on a piece of fresh spinal
cord tissue, which is difficult to render transparent with
the traditional CLARITY technique, and successfully
visualized the three-dimensional structure of the ventral
root to a depth of 508.52 lm using immunostaining for
neurofilament (Figure 1a). However, it has to be noted
that there is heterogeneity in the penetration depth of
the antibody with some parts of the spinal cord with
labelling to 89 lm only. The reasons behind the varia-
tion in penetration depth within the same piece of tissue
remain largely unknown, and we hypothesize that local
tissue structural biochemical properties or vasculature
can affect antibody penetration. Furthermore, we have
also demonstrated the potential of FASTClear with other
antibodies such as tyrosine hydroxylase (Millipore
AB152, UK) and microtubule-associated protein 2 (ab-
cam ab5392, UK) (data not shown) and on formalin-
fixed tissue in a tissue bank for the 3D visualization of
Purkinje neurons in the cerebellum (Figure 1b), with a
depth of immunolabelling to 66.5 lm.
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FASTClear is a greatly simplified and more user-
friendly tissue-clearing protocol for human brain tissues
which reduces the overall processing time from tissue
fixation to immunostaining and visualization to a mini-
mum of 16 days (Figure 2). However, it is still not
possible to achieve immunolabelling to the full thickness
Table 1. Free of acrylamide sodium dodecyl sulphate (SDS)-based tissue-clearing (FASTClear) protocol
Step Time
1. Fixation in 10% neutral-buffered formalin/4% paraformaldehyde (PFA) Minimum of 3 days at 4°C
• N.B. fixation time depends on size of fresh tissue block. Typically, a 1-cm-thick
block will take around 3 days to be fully fixed.
• This step is only required for fresh tissue. Proceed to Step 2 for formalin-fixed tissue.
Caution: use a tightly sealed container (parafilm) for fixation as formalin/PFA is toxic.
2. Dissect into smaller block
• A maximum of 3 mm in thickness is recommended due to immunolabelling diffusion
and confocal objectives working distance limits. Note that the sectioning surface should
be as flat as possible and designed to be the future imaging surface.
3. Immerse in 4% SDS buffer Minimum of 5 days
at 50°C oven• This step improves antibody labelling and it is recommended the tissue is immersed in
SDS buffer until transparency is reached. For prolonged fixed tissue (>2 years in fixation),
a 2-mm-thick block can reach transparency in 3 months.
• [However, do note that complete transparency of tissue is not a necessity as tissue will
become transparent at the final refractive index matching step]
• Frequent change in buffer (daily to twice weekly) can improve the speed of reaching transparency.
4. Washing in 0.1% phosphate-buffered saline (PBS)-Triton 3 9 1 h at 50°C
5. Blocking and permeabilization in blocking medium [0.6 M glycine, 0.2% Triton X-100, 6%
Donkey serum, 20% dimethyl sulfoxide (DMSO) in PBS]
Overnight at 37°C
• Add enough blocking medium to cover the tissue.
• Optional if the antibody is known to be of high specificity.
6. Washing in 0.1% PBS-Triton 2 x 1 h at 37°C
7. Primary antibody incubation (diluted in 0.2% Tween-20, 5% DMSO, 3% Donkey serum, 0.01%
sodium azide in PBS)
Minimum of 2 days at 37°C
• Start with a low concentration (e.g. 1:1000; 2 ll in 2 ml of diluent), supplementing antibody
daily/twice daily until a final concentration of around 1:50–1:100 is reached.
• Optimal concentration and days of incubation vary between antibodies.
• As an example, tyrosine hydroxylase antibodies (Millipore AB152) can reach complete penetration
to a depth of 2 mm on each side in 3 days at a final concentration of 1:100.
• If multiple antigen labelling is required, it is recommended to perform immunolabelling sequentially.
8. Washing in 0.1% PBS-Triton 3 9 1 h at 37°C; then
overnight at 37°C
9. Secondary antibody incubation (diluted in 0.2% Tween-20, 5% DMSO, 3% Donkey serum, 0.01%
sodium azide in PBS)
Minimum of 2 days at 37°C
• Same as Step 7 above.
• 40,6-Diamidino-2-phenylindole or fluorophore-conjugated lectin can be added at this stage
(1:100 from a stock of 1 lg/ml diluted with 1:1 water: DMSO) for better tissue orientation.
10. Washing in 0.1% PBS-Triton 5 9 1 h at 37°C; then
overnight at 37°C
11. Immersion in refractive index matching medium RT until transparency is
reached• If tissue is transparent/almost transparent after Step 3
Immerse in 47% 2,20-thiodiethanol diluted in 0.01 M PBS without saline or 70% w/v Sorbitol
in 0.1 M phosphate buffer (as previously described in ref. 3).
• If tissue is opaque after Step 3, follow 3DISCO clearing method:
Dehydrate tissue in 50% tetrahydrofuran (THF) (overnight), 70% THF (1 h), 80% THF (1 h),
100% THF (1 h) 100% THF (1 h) then dibenzyl ether until transparency is reached.
Caution: perform this step in the fume hood.
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of the tissue and this technique is yet to be optimized
for archival formalin-fixed tissues. Also, tissue that
requires clearing with organic solvent may undergo
shrinkage. Although fine structures are likely to be pre-
served, a high-power objective will be required which
often has a lower working distance. Nevertheless, with
the development of smaller molecular probes such as
nanobodies and aptamers [7], further improvement of
human brain tissue clearing will be made, leading to a
new era of three-dimensional histology.
(a) (b)
Figure 1. Human brain tissue processed and immunostained using free of acrylamide sodium dodecyl sulphate (SDS)-based tissue
clearing (FASTClear). (a) z-Stack image of a ventral root of a piece of spinal cord fresh tissue (3 mm thick) immunostained using
antineurofilament primary antibody (final concentration 1:100; Dako M0762) and Alexa-fluor 488 conjugated donkey anti-mouse
secondary antibody. Stained tissue was visualized using a Zeiss 780 inverted confocal microscope (Carl Zeiss, Germany) with 910
objective (imaging depth to 508.519 lm, z-stack step size 3.03 lm). (b) z-Stack image of a piece of fixed cerebellar tissue immunostained
using antibodies against neurofilament (green; final concentration 1:100; Dako M0762) and bIII-tubulin (red; final concentration 1:100;
Millipore AB9354) and counterstained with 40,6-diamidino-2-phenylindole (blue). Stained tissue was visualized using a Leica SP5 (Leica
Microsystems, UK) confocal microscope with 940 objective (imaging depth to 66.5 lm, z-stack step size 0.38 lm).
Figure 2. Workflow diagram of free of acrylamide sodium dodecyl sulphate (SDS)-based tissue clearing (FASTClear).
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